RCS - Avacta Group PLC - Avacta to Participate in Conference March 2026

AvactaAnnouncement

18/02/2026 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260218:nRSR3916Ta&default-theme=true

RNS Number : 3916T  Avacta Group PLC  18 February 2026

 

 

Avacta to Participate in Investor Conference in March 2026

 

 

LONDON and PHILADELPHIA - February 18, 2026 - Avacta Therapeutics (AIM: AVCT,
"the Company", "Avacta"), a clinical stage biopharmaceutical company
developing pre|CISION(®), a tumor-activated oncology delivery platform,
today announces the executive management team will participate in the TD Cowen
Investor Conference in March.

 

Christina Coughlin, CEO and Brian Hahn, CFO of Avacta, will participate in the
46th Annual TD Cowen Health Care Conference in Boston on March 3, 2026.  The
company will host investor meetings throughout the day, with a live Company
presentation at 9:10 AM ET. Investors interested in accessing the Company's
presentation may view the replay of the presentation, which will be available
after the event on the Investor Resources | Avacta Therapeutics
(https://avacta.com/investors/investor-resources/) site.

 

 

 

-Ends-

 

For further information from Avacta, please contact:

 

 Avacta Group plc                                   https://avacta.com/ (https://avacta.com/)

 Christina Coughlin, Chief Executive Officer        via Cohesion Bureau

 Strand Hanson Limited (Nominated Adviser)          www.strandhanson.co.uk (http://www.strandhanson.co.uk)

 James Harris / Chris Raggett / James Dance

 Zeus (Broker)                                      www.zeuscapital.co.uk (http://www.zeuscapital.co.uk)

 James Hornigold / George Duxberry / Dominic King

 Cohesion Bureau (Communications)                   avacta@cohesionbureau.com (mailto:avacta@cohesionbureau.com)

 Richard Jarvis / Chris Maggos

 

About Avacta - https://avacta.com/ (https://avacta.com/)

Avacta Therapeutics is a clinical-stage life sciences company expanding the
reach of highly potent cancer therapies with the pre|CISION(®) platform.
pre|CISION(®) is a proprietary payload delivery system based on a
tumor-specific protease (fibroblast activation protein or FAP) that is
designed to concentrate highly potent payloads in the tumor microenvironment
while sparing normal tissues.

 

Our innovative pipeline consists of pre|CISION(®) peptide drug conjugates
(PDC) or Affimer® drug conjugates (AffDC) that leverage the tumor-specific
release mechanism, providing unique benefits over traditional antibody drug
conjugates.

 

The pre|CISION(®) platform comprises an anticancer payload conjugated to a
proprietary peptide that is a highly specific substrate for fibroblast
activation protein (FAP) which is upregulated in most solid tumors compared
with healthy tissues. The pre|CISION(®) platform harnesses this tumor
specific protease to cleave pre|CISION(®) peptide drug conjugates and
pre|CISION(®) antibody/Affimer(®) drug conjugates in the tumor
microenvironment, thus releasing active payload in the tumor and reducing
systemic exposure and toxicity, allowing dosing to be optimized to deliver the
best outcomes for patients.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAAKOBPABKDQBD



            Copyright 2019 Regulatory News Service, all rights reserved